Trial Profile
Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Adverse reactions; Diagnostic use
- Acronyms MRTOX
- 17 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 17 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Feb 2013 Planned End Date changed from 1 Oct 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.